You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDabrafenib
Accession NumberDB08912
TypeSmall Molecule
GroupsApproved
DescriptionDabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.
Structure
Thumb
Synonyms
Dabrafenib
GSK2118436a
External Identifiers
  • GSK2118436
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tafinlarcapsule50 mg/1oralGlaxo Smith Kline Llc2013-06-10Not applicableUs
Tafinlarcapsule75 mg/1oralNovartis Pharmaceuticals Corporation2016-04-01Not applicableUs
Tafinlarcapsule75 mg/1oralGlaxo Smith Kline Llc2013-06-10Not applicableUs
Tafinlarcapsule50 mg/1oralNovartis Pharmaceuticals Corporation2016-04-12Not applicableUs
Tafinlarcapsule50 mgoralNovartis Pharmaceuticals Canada Inc2013-08-28Not applicableCanada
Tafinlarcapsule75 mgoralNovartis Pharmaceuticals Canada Inc2013-08-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dabrafenib Mesylate
Thumb
  • InChI Key: YKGMKSIHIVVYKY-UHFFFAOYSA-N
  • Monoisotopic Mass: 615.089165588
  • Average Mass: 615.668
DBSALT000036
Categories
UNIIQGP4HA4G1B
CAS numberNot Available
WeightAverage: 519.562
Monoisotopic: 519.101050904
Chemical FormulaC23H20F3N5O2S2
InChI KeyInChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N
InChI
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
IUPAC Name
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide
SMILES
CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylthiazoles. These are compounds containing a phenylthiazole moiety, which consists of an thiazole ring attached to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassThiazoles
Direct ParentPhenylthiazoles
Alternative Parents
Substituents
  • Phenylthiazole
  • Sulfanilide
  • Benzenesulfonamide
  • 2,4,5-trisubstituted 1,3-thiazole
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationDabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
PharmacodynamicsDabrafenib caused an inhibition of phosphorylated ERK. This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited.
Mechanism of actionDabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.
Related Articles
AbsorptionAfter oral administration, median time to achieve peak plasma concentration (Tmax) is 2 hours. Mean absolute bioavailability of oral dabrafenib is 95%.
Volume of distribution

Apparent volume of distribution (Vd/F) = 70.3 L.
Distribution to the brain is restricted because dabrafenib is a substrate and undergoes efflux by P-glycoprotein and breast cancer resistance protein.

Protein binding99.7% bound to human plasma protein.
Metabolism

Dabrafenib is hepatically metabolized. The biotransformation process is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-debrafenib. This metabolite is further oxidized via CYP3A4 to form carboxy-dabrafenib and subsequently excreted in bile and urine. Carboxy-dabrafenib can also undergo decarboxylation to form desmethyl-dabrafenib, which may be reabsorbed from the gut. Desmethyl-dabrafenib is further metabolized by CYP3A4 to oxidative metabolites.

Route of elimination71% of the dose is excreted in feces. 23% of the dose is excreted in the urine as metabolites only.
Half lifeDabrafenib = 8 hours; Hydroxy-dabrafenib = 10 hours; Carboxy-dabrafenib = 21-22 hours; Desmethyl-dabrafenib = 21- 22 hours.
Clearance

The apparent clearance of dabrafenib is 17.0 L/h after single dosing and 34.4 L/h after 2 weeks of twice daily dosing.

ToxicityMost common adverse reactions (≥20%) for dabrafenib are hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.7232
Caco-2 permeable+0.5069
P-glycoprotein substrateNon-substrate0.7965
P-glycoprotein inhibitor INon-inhibitor0.6468
P-glycoprotein inhibitor IINon-inhibitor0.7039
Renal organic cation transporterNon-inhibitor0.8694
CYP450 2C9 substrateNon-substrate0.8233
CYP450 2D6 substrateNon-substrate0.7346
CYP450 3A4 substrateNon-substrate0.5834
CYP450 1A2 substrateInhibitor0.5219
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.8459
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.7531
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8612
Ames testNon AMES toxic0.7078
CarcinogenicityNon-carcinogens0.8093
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4329 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.7704
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral50 mg/1
Capsuleoral50 mg
Capsuleoral75 mg
Capsuleoral75 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7994185 No2010-01-202030-01-20Us
US8415345 No2010-01-202030-01-20Us
US8703781 No2010-10-152030-10-15Us
US9233956 No2009-05-042029-05-04Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP5.44ALOGPS
logP5.46ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)7.16ChemAxon
pKa (Strongest Basic)2.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.86 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.51 m3·mol-1ChemAxon
Polarizability49.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gibney GT, Zager JS: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. [PubMed:23621583 ]
External Links
ATC CodesL01XE23
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (418 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Dabrafenib can be increased when it is combined with Abiraterone.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Dabrafenib.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dabrafenib.
AceclofenacThe serum concentration of Aceclofenac can be decreased when it is combined with Dabrafenib.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib.
AcetaminophenThe serum concentration of Dabrafenib can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dabrafenib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dabrafenib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Dabrafenib.
AfatinibThe serum concentration of Dabrafenib can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Dabrafenib.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Dabrafenib.
AlbendazoleThe serum concentration of Dabrafenib can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib.
AldosteroneThe serum concentration of Dabrafenib can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Dabrafenib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Dabrafenib.
AlfentanilThe serum concentration of Dabrafenib can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Dabrafenib.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Dabrafenib.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dabrafenib.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Dabrafenib.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Dabrafenib.
Aluminum hydroxideThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum phosphate.
AmantadineThe serum concentration of Dabrafenib can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dabrafenib.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Dabrafenib.
Aminohippuric acidThe serum concentration of Dabrafenib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Dabrafenib.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib.
AmitriptylineThe serum concentration of Dabrafenib can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Dabrafenib.
AmlodipineThe serum concentration of Dabrafenib can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be decreased when it is combined with Dabrafenib.
AmoxicillinThe serum concentration of Amoxicillin can be decreased when it is combined with Dabrafenib.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Dabrafenib.
AmsacrineThe serum concentration of Dabrafenib can be increased when it is combined with Amsacrine.
AnagrelideDabrafenib may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Dabrafenib.
AprepitantThe serum concentration of Dabrafenib can be increased when it is combined with Aprepitant.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Dabrafenib.
Arachidonic AcidThe serum concentration of Arachidonic Acid can be decreased when it is combined with Dabrafenib.
ArformoterolThe serum concentration of Arformoterol can be decreased when it is combined with Dabrafenib.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Dabrafenib.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.
Arsenic trioxideDabrafenib may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.
AsenapineThe serum concentration of Dabrafenib can be decreased when it is combined with Asenapine.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Dabrafenib.
AstemizoleThe serum concentration of Dabrafenib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Dabrafenib.
AtazanavirThe serum concentration of Dabrafenib can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Dabrafenib can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Atomoxetine can be decreased when it is combined with Dabrafenib.
AtomoxetineThe metabolism of Dabrafenib can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.
AtorvastatinThe serum concentration of Dabrafenib can be increased when it is combined with Atorvastatin.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Dabrafenib.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dabrafenib.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.
AzelastineThe serum concentration of Dabrafenib can be increased when it is combined with Azelastine.
AzithromycinDabrafenib may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Dabrafenib can be increased when it is combined with Azithromycin.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Dabrafenib.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dabrafenib.
BenzatropineThe serum concentration of Benzatropine can be decreased when it is combined with Dabrafenib.
BenzocaineThe serum concentration of Dabrafenib can be increased when it is combined with Benzocaine.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib.
BepridilThe serum concentration of Dabrafenib can be increased when it is combined with Bepridil.
BeraprostThe serum concentration of Beraprost can be decreased when it is combined with Dabrafenib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Dabrafenib.
BexaroteneThe serum concentration of Dabrafenib can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib.
BiperidenThe serum concentration of Dabrafenib can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Dabrafenib can be decreased when it is combined with Bismuth Subcitrate.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Dabrafenib.
BoceprevirThe metabolism of Dabrafenib can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.
BortezomibThe metabolism of Dabrafenib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dabrafenib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib.
BosutinibThe serum concentration of Dabrafenib can be increased when it is combined with Bosutinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.
BromocriptineThe serum concentration of Dabrafenib can be increased when it is combined with Bromocriptine.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dabrafenib.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.
BuprenorphineThe serum concentration of Dabrafenib can be increased when it is combined with Buprenorphine.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Dabrafenib.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.
BuspironeThe serum concentration of Dabrafenib can be increased when it is combined with Buspirone.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Dabrafenib.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.
CabazitaxelThe serum concentration of Dabrafenib can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dabrafenib.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Dabrafenib.
CaffeineThe serum concentration of Dabrafenib can be increased when it is combined with Caffeine.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib.
Calcium carbonateThe serum concentration of Dabrafenib can be decreased when it is combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dabrafenib.
CanagliflozinThe serum concentration of Dabrafenib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Candesartan can be decreased when it is combined with Dabrafenib.
CandesartanThe serum concentration of Dabrafenib can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Dabrafenib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Dabrafenib.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Dabrafenib.
CarisoprodolThe serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib.
CarvedilolThe serum concentration of Dabrafenib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Dabrafenib can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dabrafenib.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.
CelecoxibThe metabolism of Dabrafenib can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Dabrafenib.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Dabrafenib.
CeritinibThe serum concentration of Dabrafenib can be increased when it is combined with Ceritinib.
CeritinibDabrafenib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dabrafenib.
ChloramphenicolThe serum concentration of Chloramphenicol can be decreased when it is combined with Dabrafenib.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dabrafenib.
ChloroquineDabrafenib may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Dabrafenib can be increased when it is combined with Chloroquine.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib.
ChlorpromazineDabrafenib may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Dabrafenib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dabrafenib.
ChlorpropamideThe serum concentration of Dabrafenib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dabrafenib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Dabrafenib.
CholesterolThe serum concentration of Dabrafenib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Dabrafenib can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dabrafenib.
CilazaprilThe serum concentration of Dabrafenib can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Dabrafenib.
CimetidineThe serum concentration of Dabrafenib can be decreased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib.
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib.
CiprofloxacinDabrafenib may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Dabrafenib can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Dabrafenib.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.
CitalopramThe serum concentration of Dabrafenib can be increased when it is combined with Citalopram.
ClarithromycinDabrafenib may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Dabrafenib can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Dabrafenib can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Dabrafenib.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dabrafenib.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Dabrafenib.
ClofazimineThe serum concentration of Dabrafenib can be increased when it is combined with Clofazimine.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Dabrafenib.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Dabrafenib.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib.
ClomipramineThe serum concentration of Dabrafenib can be increased when it is combined with Clomipramine.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Dabrafenib.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib.
ClopidogrelThe metabolism of Dabrafenib can be decreased when combined with Clopidogrel.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Dabrafenib.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Dabrafenib.
ClotrimazoleThe metabolism of Dabrafenib can be decreased when combined with Clotrimazole.
ClozapineDabrafenib may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Dabrafenib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Dabrafenib.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Dabrafenib.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Dabrafenib.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Dabrafenib.
ColchicineThe serum concentration of Dabrafenib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Dabrafenib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Dabrafenib can be increased when it is combined with Conivaptan.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Dabrafenib.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Dabrafenib.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib.
CrizotinibDabrafenib may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Dabrafenib can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dabrafenib.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.
CyclosporineThe metabolism of Dabrafenib can be decreased when combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Dabrafenib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dabrafenib can be increased when it is combined with Dactinomycin.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Dabrafenib.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Dabrafenib.
DarunavirThe metabolism of Dabrafenib can be decreased when combined with Darunavir.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Dabrafenib can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Dabrafenib.
DeferasiroxThe serum concentration of Dabrafenib can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Dabrafenib.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dabrafenib.
DelavirdineThe metabolism of Dabrafenib can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.
DesipramineThe serum concentration of Dabrafenib can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dabrafenib.
DesloratadineThe serum concentration of Dabrafenib can be increased when it is combined with Desloratadine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.
DexamethasoneThe serum concentration of Dabrafenib can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib.
DextromethorphanThe serum concentration of Dabrafenib can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dabrafenib.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib.
DiclofenacThe serum concentration of Dabrafenib can be increased when it is combined with Diclofenac.
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Dabrafenib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dabrafenib.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.
DigoxinDigoxin may decrease the cardiotoxic activities of Dabrafenib.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dabrafenib.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.
DihydroergotamineThe metabolism of Dabrafenib can be decreased when combined with Dihydroergotamine.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Dabrafenib.
DiltiazemThe metabolism of Dabrafenib can be decreased when combined with Diltiazem.
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib.
DipyridamoleThe serum concentration of Dabrafenib can be increased when it is combined with Dipyridamole.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Dabrafenib.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dabrafenib.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib.
DolasetronDabrafenib may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Dabrafenib.
DopamineThe serum concentration of Dopamine can be decreased when it is combined with Dabrafenib.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Dabrafenib.
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.
DoxazosinThe serum concentration of Dabrafenib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Dabrafenib can be decreased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib.
DoxycyclineThe metabolism of Dabrafenib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Dabrafenib.
DronabinolThe serum concentration of Dabrafenib can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Dabrafenib.
DronedaroneThe metabolism of Dabrafenib can be decreased when combined with Dronedarone.
DroperidolDabrafenib may increase the QTc-prolonging activities of Droperidol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Dabrafenib.
EfavirenzThe serum concentration of Dabrafenib can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Dabrafenib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Dabrafenib.
EltrombopagThe serum concentration of Dabrafenib can be increased when it is combined with Eltrombopag.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dabrafenib.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Dabrafenib.
EnalaprilThe serum concentration of Dabrafenib can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be decreased when it is combined with Dabrafenib.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib.
EnzalutamideThe serum concentration of Dabrafenib can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Dabrafenib can be decreased when it is combined with Epinastine.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.
EpoprostenolThe serum concentration of Epoprostenol can be decreased when it is combined with Dabrafenib.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Dabrafenib.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Dabrafenib.
ErgonovineThe serum concentration of Dabrafenib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Dabrafenib.
ErgotamineThe serum concentration of Dabrafenib can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.
ErythromycinDabrafenib may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Dabrafenib can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
Eslicarbazepine acetateThe serum concentration of Dabrafenib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Dabrafenib can be decreased when it is combined with Esomeprazole.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Dabrafenib.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Dabrafenib.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Dabrafenib.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Dabrafenib.
EstramustineThe serum concentration of Dabrafenib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Dabrafenib can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Dabrafenib.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Dabrafenib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabrafenib.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Dabrafenib.
EtodolacThe serum concentration of Etodolac can be decreased when it is combined with Dabrafenib.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Dabrafenib.
EtoposideThe serum concentration of Dabrafenib can be increased when it is combined with Etoposide.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.
EtravirineThe serum concentration of Dabrafenib can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Dabrafenib.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dabrafenib.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Dabrafenib.
FamotidineThe serum concentration of Famotidine can be decreased when it is combined with Dabrafenib.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.
FelodipineThe serum concentration of Dabrafenib can be increased when it is combined with Felodipine.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dabrafenib.
FentanylThe serum concentration of Dabrafenib can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.
FexofenadineThe serum concentration of Dabrafenib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Dabrafenib can be increased when it is combined with Fidaxomicin.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Dabrafenib.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Dabrafenib.
FlecainideDabrafenib may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.
FluconazoleThe metabolism of Dabrafenib can be decreased when combined with Fluconazole.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib.
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.
FluoxetineThe serum concentration of Dabrafenib can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Dabrafenib can be increased when it is combined with Flupentixol.
FlupentixolDabrafenib may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Dabrafenib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib.
FlurazepamThe serum concentration of Dabrafenib can be increased when it is combined with Flurazepam.
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Dabrafenib.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dabrafenib.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Dabrafenib.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib.
FluvoxamineThe metabolism of Dabrafenib can be decreased when combined with Fluvoxamine.
FormoterolThe serum concentration of Formoterol can be decreased when it is combined with Dabrafenib.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dabrafenib.
FosamprenavirThe metabolism of Dabrafenib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dabrafenib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib.
FosphenytoinThe metabolism of Dabrafenib can be increased when combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Dabrafenib.
Fusidic AcidThe serum concentration of Dabrafenib can be increased when it is combined with Fusidic Acid.
Gadobenic acidDabrafenib may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Dabrafenib.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib.
GefitinibThe serum concentration of Dabrafenib can be increased when it is combined with Gefitinib.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Dabrafenib.
GemfibrozilThe metabolism of Dabrafenib can be decreased when combined with Gemfibrozil.
GemifloxacinDabrafenib may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Dabrafenib can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dabrafenib.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dabrafenib.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dabrafenib.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dabrafenib.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dabrafenib.
GlucosamineThe serum concentration of Glucosamine can be decreased when it is combined with Dabrafenib.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dabrafenib.
GlyburideThe serum concentration of Dabrafenib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Dabrafenib can be increased when it is combined with Glycerol.
GoserelinDabrafenib may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Dabrafenib can be increased when it is combined with Gramicidin D.
GranisetronDabrafenib may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib.
GrepafloxacinThe serum concentration of Dabrafenib can be increased when it is combined with Grepafloxacin.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Dabrafenib.
HaloperidolDabrafenib may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Dabrafenib can be increased when it is combined with Haloperidol.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Dabrafenib.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Dabrafenib.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Dabrafenib.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.
HydrocortisoneThe serum concentration of Dabrafenib can be increased when it is combined with Hydrocortisone.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dabrafenib.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Dabrafenib.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib.
IbutilideDabrafenib may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib.
IdelalisibThe serum concentration of Dabrafenib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dabrafenib resulting in a loss in efficacy.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Dabrafenib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.
ImatinibThe metabolism of Dabrafenib can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.
ImipramineThe serum concentration of Dabrafenib can be increased when it is combined with Imipramine.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Dabrafenib.
indisulamThe serum concentration of indisulam can be decreased when it is combined with Dabrafenib.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.
IndomethacinThe serum concentration of Dabrafenib can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dabrafenib.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dabrafenib.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dabrafenib.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dabrafenib.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dabrafenib.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dabrafenib.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.
IrbesartanThe serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.
IrbesartanThe metabolism of Dabrafenib can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Dabrafenib.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Dabrafenib.
IsavuconazoniumThe metabolism of Dabrafenib can be decreased when combined with Isavuconazonium.
IsofluraneThe serum concentration of Isoflurane can be decreased when it is combined with Dabrafenib.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dabrafenib.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dabrafenib.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Dabrafenib.
IsradipineThe metabolism of Dabrafenib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Dabrafenib.
ItraconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Dabrafenib.
IvacaftorThe serum concentration of Dabrafenib can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Dabrafenib.
IvermectinThe serum concentration of Dabrafenib can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dabrafenib.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.
KetamineThe serum concentration of Dabrafenib can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dabrafenib.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Dabrafenib.
KetoconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Ketoconazole.
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.
LansoprazoleThe serum concentration of Dabrafenib can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dabrafenib.
LapatinibThe serum concentration of Dabrafenib can be increased when it is combined with Lapatinib.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Dabrafenib.
LeflunomideThe serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib.
LenvatinibDabrafenib may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.
LesinuradThe serum concentration of Lesinurad can be decreased when it is combined with Dabrafenib.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Dabrafenib.
LeuprolideDabrafenib may increase the QTc-prolonging activities of Leuprolide.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Dabrafenib.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib.
LevofloxacinDabrafenib may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Dabrafenib can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dabrafenib.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Dabrafenib.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Dabrafenib.
LicofeloneThe serum concentration of Licofelone can be decreased when it is combined with Dabrafenib.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.
LidocaineThe serum concentration of Dabrafenib can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Dabrafenib.
LiothyronineThe serum concentration of Dabrafenib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dabrafenib can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dabrafenib.
LisinoprilThe serum concentration of Dabrafenib can be increased when it is combined with Lisinopril.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Dabrafenib.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Dabrafenib.
LomitapideThe serum concentration of Dabrafenib can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Dabrafenib.
LoperamideThe serum concentration of Dabrafenib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.
LopinavirThe serum concentration of Dabrafenib can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Dabrafenib.
LoratadineThe serum concentration of Dabrafenib can be increased when it is combined with Loratadine.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib.
LornoxicamThe serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.
LosartanThe serum concentration of Dabrafenib can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Dabrafenib.
LovastatinThe metabolism of Dabrafenib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Dabrafenib can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib.
LumiracoxibThe serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Dabrafenib.
MagaldrateThe serum concentration of Dabrafenib can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.
Magnesium TrisilicateThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Trisilicate.
MalathionThe serum concentration of Malathion can be decreased when it is combined with Dabrafenib.
MaprotilineThe serum concentration of Dabrafenib can be increased when it is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Dabrafenib.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Dabrafenib.
MebendazoleThe serum concentration of Dabrafenib can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.
Mefenamic acidThe serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib.
MefloquineThe serum concentration of Dabrafenib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Dabrafenib can be increased when it is combined with Megestrol acetate.
MelatoninThe serum concentration of Melatonin can be decreased when it is combined with Dabrafenib.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Dabrafenib.
MeprobamateThe serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.
MeprobamateThe serum concentration of Dabrafenib can be increased when it is combined with Meprobamate.
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Dabrafenib.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.
MethadoneDabrafenib may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Dabrafenib can be increased when it is combined with Methadone.
MethanthelineThe serum concentration of Dabrafenib can be decreased when it is combined with Methantheline.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Dabrafenib.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Dabrafenib.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib.
MethsuximideThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Dabrafenib.
MetiamideThe serum concentration of Dabrafenib can be decreased when it is combined with Metiamide.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Dabrafenib.
MetoprololThe serum concentration of Dabrafenib can be increased when it is combined with Metoprolol.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Dabrafenib.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Dabrafenib.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Dabrafenib.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Dabrafenib.
MibefradilThe serum concentration of Dabrafenib can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Dabrafenib.
MiconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Dabrafenib.
MifepristoneThe metabolism of Dabrafenib can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Dabrafenib.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dabrafenib.
MitomycinThe serum concentration of Dabrafenib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Dabrafenib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Dabrafenib can be decreased when it is combined with Mitoxantrone.
MoclobemideThe serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.
ModafinilThe serum concentration of Dabrafenib can be decreased when it is combined with Modafinil.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Dabrafenib.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dabrafenib.
MorphineThe serum concentration of Dabrafenib can be increased when it is combined with Morphine.
MoxifloxacinDabrafenib may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe serum concentration of muraglitazar can be decreased when it is combined with Dabrafenib.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.
NafcillinThe serum concentration of Dabrafenib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Dabrafenib.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Dabrafenib.
NaltrexoneThe serum concentration of Dabrafenib can be increased when it is combined with Naltrexone.
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Dabrafenib.
NaringeninThe serum concentration of Dabrafenib can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Dabrafenib.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Dabrafenib.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib.
NeostigmineThe serum concentration of Dabrafenib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Dabrafenib can be increased when it is combined with Netupitant.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Dabrafenib.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib.
NevirapineThe metabolism of Dabrafenib can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.
NicardipineThe serum concentration of Dabrafenib can be increased when it is combined with Nicardipine.
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Dabrafenib.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Dabrafenib.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dabrafenib.
NilotinibThe metabolism of Dabrafenib can be decreased when combined with Nilotinib.
NilutamideThe serum concentration of Nilutamide can be decreased when it is combined with Dabrafenib.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Dabrafenib.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.
NisoldipineThe serum concentration of Dabrafenib can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib.
NitrazepamThe serum concentration of Dabrafenib can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.
NitrendipineThe serum concentration of Dabrafenib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Dabrafenib can be decreased when it is combined with Nizatidine.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Dabrafenib.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib.
OfloxacinDabrafenib may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.
OlaparibThe metabolism of Dabrafenib can be decreased when combined with Olaparib.
OlodaterolThe serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.
OmeprazoleThe serum concentration of Dabrafenib can be increased when it is combined with Omeprazole.
OndansetronDabrafenib may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib.
OsimertinibThe serum concentration of Dabrafenib can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Dabrafenib.
OuabainOuabain may decrease the cardiotoxic activities of Dabrafenib.
OxaprozinThe serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Dabrafenib.
OxiconazoleThe serum concentration of Oxiconazole can be decreased when it is combined with Dabrafenib.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib.
P-NitrophenolThe serum concentration of Dabrafenib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.
PaclitaxelThe serum concentration of Dabrafenib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Dabrafenib can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.
PaliperidoneDabrafenib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Dabrafenib can be increased when it is combined with Palmitic Acid.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Dabrafenib.
PanobinostatDabrafenib may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Dabrafenib.
PantoprazoleThe serum concentration of Dabrafenib can be increased when it is combined with Pantoprazole.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Dabrafenib.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Dabrafenib.
ParoxetineThe serum concentration of Dabrafenib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dabrafenib.
PentamidineDabrafenib may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib.
PentobarbitalThe metabolism of Dabrafenib can be increased when combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Dabrafenib.
PerflutrenDabrafenib may increase the QTc-prolonging activities of Perflutren.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Dabrafenib.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Dabrafenib.
PerindoprilThe serum concentration of Dabrafenib can be increased when it is combined with Perindopril.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Dabrafenib.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Dabrafenib.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Dabrafenib.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Dabrafenib.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dabrafenib.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dabrafenib.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib.
PhenylbutazoneThe serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib.
PhenytoinThe metabolism of Dabrafenib can be increased when combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Dabrafenib.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Dabrafenib.
PimozideThe serum concentration of Dabrafenib can be increased when it is combined with Pimozide.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Dabrafenib.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dabrafenib.
PioglitazoneThe metabolism of Dabrafenib can be decreased when combined with Pioglitazone.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib.
PiroxicamThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib.
Platelet Activating FactorThe serum concentration of Dabrafenib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Dabrafenib.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib.
PonatinibThe serum concentration of Dabrafenib can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Dabrafenib.
PosaconazoleThe serum concentration of Dabrafenib can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dabrafenib.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Dabrafenib.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib.
PravastatinThe serum concentration of Dabrafenib can be increased when it is combined with Pravastatin.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Dabrafenib.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib.
PrazosinThe serum concentration of Dabrafenib can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Dabrafenib.
PrednisoneThe serum concentration of Dabrafenib can be increased when it is combined with Prednisone.
PrimaquineDabrafenib may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Primidone can be decreased when it is combined with Dabrafenib.
PrimidoneThe metabolism of Dabrafenib can be increased when combined with Primidone.
ProbenecidThe serum concentration of Dabrafenib can be increased when it is combined with Probenecid.
ProcainamideDabrafenib may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Dabrafenib.
PromazineDabrafenib may increase the QTc-prolonging activities of Promazine.
PromethazineThe serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.
PromethazineThe serum concentration of Dabrafenib can be increased when it is combined with Promethazine.
PropafenoneDabrafenib may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Dabrafenib can be increased when it is combined with Propafenone.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Dabrafenib.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.
PropranololThe serum concentration of Dabrafenib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Dabrafenib can be increased when it is combined with Protriptyline.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Dabrafenib.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Dabrafenib.
QuercetinThe serum concentration of Dabrafenib can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Dabrafenib.
QuinacrineThe serum concentration of Dabrafenib can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Dabrafenib.
QuinidineThe serum concentration of Dabrafenib can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Dabrafenib.
QuinineThe serum concentration of Dabrafenib can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib.
RabeprazoleThe metabolism of Dabrafenib can be decreased when combined with Rabeprazole.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Dabrafenib.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Dabrafenib.
RanolazineThe serum concentration of Dabrafenib can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dabrafenib.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib.
ReboxetineThe serum concentration of Dabrafenib can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib.
RegorafenibThe serum concentration of Dabrafenib can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Dabrafenib.
ReserpineThe serum concentration of Dabrafenib can be decreased when it is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Dabrafenib.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Dabrafenib.
RifabutinThe metabolism of Dabrafenib can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Dabrafenib.
RifapentineThe metabolism of Dabrafenib can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib.
RilpivirineThe serum concentration of Dabrafenib can be increased when it is combined with Rilpivirine.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Dabrafenib.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Dabrafenib.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Dabrafenib.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Dabrafenib.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dabrafenib.
RolapitantThe serum concentration of Dabrafenib can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Dabrafenib.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dabrafenib.
RosiglitazoneThe metabolism of Dabrafenib can be decreased when combined with Rosiglitazone.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib.
Roxatidine acetateThe serum concentration of Dabrafenib can be decreased when it is combined with Roxatidine acetate.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Dabrafenib.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Dabrafenib.
SaquinavirDabrafenib may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Dabrafenib can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dabrafenib.
ScopolamineThe serum concentration of Dabrafenib can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Dabrafenib can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Dabrafenib.
SelegilineThe serum concentration of Dabrafenib can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dabrafenib.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Dabrafenib.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Dabrafenib.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Dabrafenib.
SertralineThe serum concentration of Dabrafenib can be increased when it is combined with Sertraline.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib.
SildenafilThe metabolism of Dabrafenib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.
SiltuximabThe serum concentration of Dabrafenib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dabrafenib can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Dabrafenib.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib.
SimvastatinThe serum concentration of Dabrafenib can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dabrafenib.
SitaxentanThe serum concentration of Sitaxentan can be decreased when it is combined with Dabrafenib.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dabrafenib.
SorafenibThe serum concentration of Dabrafenib can be increased when it is combined with Sorafenib.
SotalolDabrafenib may increase the QTc-prolonging activities of Sotalol.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Dabrafenib.
SpironolactoneThe serum concentration of Dabrafenib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Dabrafenib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Dabrafenib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Dabrafenib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Dabrafenib can be decreased when it is combined with Streptozocin.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib.
SulfamethoxazoleThe metabolism of Dabrafenib can be decreased when combined with Sulfamethoxazole.
SulfamoxoleThe serum concentration of Sulfamoxole can be decreased when it is combined with Dabrafenib.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib.
SulfinpyrazoneThe serum concentration of Dabrafenib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleDabrafenib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Dabrafenib can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dabrafenib.
SumatriptanThe serum concentration of Dabrafenib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.
SunitinibThe serum concentration of Dabrafenib can be increased when it is combined with Sunitinib.
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabrafenib.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib.
TacrineThe serum concentration of Dabrafenib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Dabrafenib.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Dabrafenib.
TAK-390MRThe serum concentration of Dabrafenib can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.
TapentadolThe serum concentration of Tapentadol can be decreased when it is combined with Dabrafenib.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Dabrafenib.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Dabrafenib.
Taurocholic AcidThe serum concentration of Dabrafenib can be increased when it is combined with Taurocholic Acid.
TazaroteneThe serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dabrafenib.
TelaprevirThe metabolism of Dabrafenib can be decreased when combined with Telaprevir.
TelavancinDabrafenib may increase the QTc-prolonging activities of Telavancin.
TelithromycinDabrafenib may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Dabrafenib can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Dabrafenib can be increased when it is combined with Telmisartan.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Dabrafenib.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.
TemsirolimusThe serum concentration of Dabrafenib can be increased when it is combined with Temsirolimus.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Dabrafenib.
TenoxicamThe serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib.
TerazosinThe serum concentration of Dabrafenib can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Dabrafenib.
TerfenadineThe serum concentration of Dabrafenib can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Dabrafenib can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Dabrafenib.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Dabrafenib.
TestosteroneThe serum concentration of Dabrafenib can be increased when it is combined with Testosterone.
TetrabenazineDabrafenib may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib.
ThalidomideThe serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dabrafenib.
ThiamylalThe serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Dabrafenib.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.
TicagrelorThe serum concentration of Dabrafenib can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib.
TiclopidineThe metabolism of Dabrafenib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Dabrafenib.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Dabrafenib.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Dabrafenib.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Dabrafenib.
TocilizumabThe serum concentration of Dabrafenib can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Dabrafenib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dabrafenib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dabrafenib.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib.
TolvaptanThe serum concentration of Dabrafenib can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dabrafenib.
TorasemideThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Dabrafenib.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Dabrafenib.
TrametinibThe risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dabrafenib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dabrafenib.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Dabrafenib.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Dabrafenib.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dabrafenib.
TrifluoperazineThe serum concentration of Dabrafenib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dabrafenib can be increased when it is combined with Triflupromazine.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.
TrimipramineThe serum concentration of Dabrafenib can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Dabrafenib.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Dabrafenib.
TroleandomycinThe serum concentration of Dabrafenib can be increased when it is combined with Troleandomycin.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Dabrafenib.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Dabrafenib.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib.
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Dabrafenib.
ValsartanThe serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Dabrafenib.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Dabrafenib.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Dabrafenib.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib.
VenlafaxineThe metabolism of Dabrafenib can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.
VerapamilThe metabolism of Dabrafenib can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Dabrafenib.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Dabrafenib.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib.
VinorelbineThe serum concentration of Dabrafenib can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dabrafenib.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dabrafenib.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib.
VoriconazoleThe metabolism of Dabrafenib can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Dabrafenib.
XimelagatranThe serum concentration of Ximelagatran can be decreased when it is combined with Dabrafenib.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dabrafenib.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Dabrafenib.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.
ZaltoprofenThe serum concentration of Zaltoprofen can be decreased when it is combined with Dabrafenib.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Dabrafenib.
ZimelidineThe serum concentration of Dabrafenib can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib.
ZiprasidoneThe metabolism of Dabrafenib can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Dabrafenib.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Dabrafenib.
ZuclopenthixolDabrafenib may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • When taken with a fatty meal, Cmax and AUC decreased. Tmax is also prolonged compared to the fasted condition.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.
Gene Name:
BRAF
Uniprot ID:
P15056
Molecular Weight:
84436.135 Da
References
  1. Gibney GT, Zager JS: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. [PubMed:23621583 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that com...
Gene Name:
RAF1
Uniprot ID:
P04049
Molecular Weight:
73051.025 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1 and CRTC2/TORC2. Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: r...
Gene Name:
SIK1
Uniprot ID:
P57059
Molecular Weight:
84901.25 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation.
Gene Name:
NEK11
Uniprot ID:
Q8NG66
Molecular Weight:
74191.62 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics. Acts downstream of several Rho family GTPase signal transduction pathways. Activated by upstream kinases including ROCK1, PAK1 and PAK4, which phosphorylate LIMK1 on a threonine residue located in its activation loop. LIMK1 subsequently phosphorylates and inactivates the actin binding/depo...
Gene Name:
LIMK1
Uniprot ID:
P53667
Molecular Weight:
72584.4 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF: Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17. [PubMed:23249624 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF: Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17. [PubMed:23249624 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
Comments
comments powered by Disqus
Drug created on June 24, 2013 15:54 / Updated on September 29, 2016 02:35